EU regulator declines to back Mirati's lung cancer drug
21/07/2023 11:19
July 21 (Reuters) - Mirati Therapeutics MRTX.O said on Friday the European regulator's panel for medical products has declined to recommend an authorization for the company's drug to treat of a type of lung cancer. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)